MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 05-06-2026
Kamada Ltd. Book Value 2011-2026 | KMDA
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Kamada Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 379 M | 372 M | 355 M | 322 M | 319 M | 179 M | 135 M | 112 M | 89.5 M | 66.7 M | 72.5 M | 80.4 M | 90 M | 28.4 M | 22.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 379 M | 22.7 M | 175 M |
Quarterly Book Value Kamada Ltd.
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 379 M | 377 M | 368 M | 375 M | 372 M | 351 M | 351 M | 343 K | 355 M | 337 K | 314 M | 317 M | - | - | - | - | 319 M | 217 M | - | - | 211 M | 206 M | - | - | 174 M | - | - | - | 138 M | - | - | - | 122 M | - | - | - | 99.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 379 M | 337 K | 252 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
5.1 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
29 M | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | USA |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.63 | -4.4 % | $ 191 M | USA |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
282 M | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B |  Britain |
 |
Enlivex Therapeutics Ltd.
ENLV
|
1.93 B | $ 0.73 | -0.03 % | $ 33.4 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 7.83 | -5.21 % | $ 214 M | Israel |
 |
Athira Pharma
ATHA
|
27.8 M | - | - | $ 269 M | USA |
 |
Esperion Therapeutics
ESPR
|
-302 M | $ 3.12 | - | $ 649 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
99.6 M | - | 0.74 % | $ 768 M | Israel |
 |
Exelixis
EXEL
|
2.16 B | $ 51.1 | -0.37 % | $ 13.9 B | USA |
|
Forte Biosciences
FBRX
|
61 M | $ 23.96 | -2.84 % | $ 310 M | USA |
|
Galera Therapeutics
GRTX
|
6.55 M | - | -32.59 % | $ 7.61 M | USA |
 |
Karyopharm Therapeutics
KPTI
|
-293 M | $ 8.9 | 0.56 % | $ 1.08 M | USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 4.4 | -7.76 % | $ 1.31 B | Canada |
 |
Midatech Pharma plc
MTP
|
11.4 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
789 M | $ 17.3 | -5.57 % | $ 809 M | USA |
 |
BioNTech SE
BNTX
|
19.2 B | $ 91.99 | -0.26 % | $ 22.2 B | Germany |
 |
Compugen Ltd.
CGEN
|
132 M | $ 3.03 | 6.32 % | $ 283 M | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
69.5 M | - | - | $ 231 M | USA |
 |
Gilead Sciences
GILD
|
59 B | $ 132.06 | -0.74 % | $ 164 B | USA |
 |
Genmab A/S
GMAB
|
36.7 B | $ 26.9 | 1.32 % | $ 1.74 B |  Danmark |
 |
Genprex
GNPX
|
7.96 M | $ 0.86 | 1.2 % | $ 802 K | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.49 | -4.12 % | $ 5.75 M | Israel |
 |
Aeterna Zentaris
AEZS
|
3.84 M | - | 5.93 % | $ 314 M | Canada |
 |
Grifols, S.A.
GRFS
|
8.61 B | $ 7.79 | 1.04 % | $ 5.29 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Fortress Biotech
FBIO
|
62.2 M | $ 2.3 | 3.14 % | $ 64.2 M | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 21.57 | -0.55 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
35.5 M | $ 9.24 | 36.48 % | $ 264 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |